<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02375139</url>
  </required_header>
  <id_info>
    <org_study_id>DA-1229_01</org_study_id>
    <nct_id>NCT02375139</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Investigate Safety/Tolerability and Pharmacokinetics of DA-1229_01(Evogliptin/Metformin XR 2.5/500 mg x 2 Tablets) Compared to Co-administration of Evogliptin 5 mg and Metformin XR 1000 mg in Healthy Male Volunteers</brief_title>
  <official_title>A Randomized, Open-label, Crossover, Single Dose Clinical Trial to Investigate Safety/Tolerability and Pharmacokinetics of DA-1229_01 (Evogliptin/Metformin XR 2.5/500 mg x 2 Tablets) Compared to Co-administration of Evogliptin 5 mg and Metformin XR 1000 mg After Single Oral Administration in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dong-A ST Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dong-A ST Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase I clinical study is to evaluate the safety/tolerability and pharmacokinetics of
      DA-1229_01(Evogliptin/Metformin XR 2.5/500 mg x 2 tablets).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under Curve(AUC)last of Evogliptin and Metformin</measure>
    <time_frame>1d(15d) pre-dose, 1,2,3,4,5,6,7,8,10,12,15,24,36,48,60,72h post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum of concentration (Cmax) of Evogliptin and Metformin</measure>
    <time_frame>1d(15d) pre-dose, 1,2,3,4,5,6,7,8,10,12,15,24,36,48,60,72h post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time of maximum concentration(Tmax) of Evogliptin and Metformin</measure>
    <time_frame>1d(15d) pre-dose, 1,2,3,4,5,6,7,8,10,12,15,24,36,48,60,72h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life(t1/2) of Evogliptin and Metformin</measure>
    <time_frame>1d(15d) pre-dose, 1,2,3,4,5,6,7,8,10,12,15,24,36,48,60,72h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Clearance(CL/F) of Evogliptin and Metformin</measure>
    <time_frame>1d(15d) pre-dose, 1,2,3,4,5,6,7,8,10,12,15,24,36,48,60,72h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under Curve(AUC)inf of Evogliptin and Metformin</measure>
    <time_frame>1d(15d) pre-dose, 1,2,3,4,5,6,7,8,10,12,15,24,36,48,60,72h post-dose</time_frame>
    <description>AUCinf = AUC last + Clast/λz</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>DA-1229_01 → E+M</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DA-1229_01 : Evogliptin/Metformin XR 2.5/500mg x 2 Tablets E : Evogliptin 5 mg M : Metformin XR 1000 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>E+M → DA-1229_01</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DA-1229_01 : Evogliptin/Metformin XR 2.5/500mg x 2 Tablets E : Evogliptin 5 mg M : Metformin XR 1000 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DA-1229_01</intervention_name>
    <description>complex single administration</description>
    <arm_group_label>DA-1229_01 → E+M</arm_group_label>
    <arm_group_label>E+M → DA-1229_01</arm_group_label>
    <other_name>Evogliptin/Metformin XR 2.5/500 mg x 2 Tablets</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E+M</intervention_name>
    <description>co-administration of 2 drugs</description>
    <arm_group_label>DA-1229_01 → E+M</arm_group_label>
    <arm_group_label>E+M → DA-1229_01</arm_group_label>
    <other_name>Evogliptin 5 mg + Metformin XR 1000 mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 19 to 45, healthy male subjects(at screening)

          -  Body weight between 55kg - 90kg, BMI between 18.0 - 27.0

          -  FPG 60-125mg/dL glucose level(at screening)

          -  Volunteer who totally understands the progress of this clinical trials, make decision
             by his free will, and signed a consent form to follow the progress.

        Exclusion Criteria:

          -  Volunteer who has past or present history of any diseases following below.(liver
             including hepatitis virus carrier, kidney, Neurology, immunology, pulmonary,
             endocrine, hematooncology, cardiology, mental disorder)

          -  Volunteer who had GI tract disease(Crohn's disease, ulcer, acute or chronic
             pancreatitis) or surgery(appendectomy, hernioplasty are excluded)

          -  Volunteer who had drug(Aspirin, antibiotics) hypersensitivity reaction

          -  Subject who already participated in other trials in 2 months

          -  Subject who had whole blood donation in 2 months, or component blood donation in 1
             months or transfusion
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyung-sang Yu, Ph.D, M.B.A</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Trial Center, Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2015</study_first_submitted>
  <study_first_submitted_qc>February 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2015</study_first_posted>
  <last_update_submitted>July 21, 2015</last_update_submitted>
  <last_update_submitted_qc>July 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

